BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

11 articles for JR Kenny

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.EBI
Genentech
2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.EBI
Genentech
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.EBI
Argenta Discovery
Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.EBI
Genentech
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.EBI
Genentech
Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.EBI
Genentech
Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.EBI
Genentech
Discovery of novel PI3-kinased specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.EBI
Genentech
Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.EBI
Genentech
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.EBI
Argenta Discovery
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.EBI
Genentech